{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:43:53Z","timestamp":1790045033126,"version":"4.0.1"},"reference-count":64,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Indonesian Education Scholarships (BPI), Center for Higher Education Funding and Assessment (PPAPT), Ministry of Higher Education, Science, and Technology of Republic Indonesia","award":["202209092870"],"award-info":[{"award-number":["202209092870"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Sciences"],"abstract":"<jats:p>Background\/Objectives: The use of linezolid in drug-resistant tuberculosis has shown good effectiveness but has a high risk of adverse drug reactions (ADRs). Linezolid-related ADRs have been widely reported and may affect their therapeutic effect. This systematic review aimed to describe linezolid-related ADRs in drug-resistant tuberculosis. Methods: This literature review was conducted on PubMed, Scopus, ProQuest, and Sage without year limitation, up to June 2023. Study quality was assessed using the JBI checklist to evaluate method quality and risk of bias in the included articles. Inclusion criteria included studies assessing linezolid-correlated ADRs in drug-resistant tuberculosis patients with individual regimens, having access to the full text, and using the English or Indonesian language. Potential reporting bias was minimized by comprehensive database search and duplicate screening. Results: Initially, we identified 650 potential studies. Upon further assessment for relevance and eligibility, seven articles were selected for analysis. From seven articles, it was shown that all articles were reporting about linezolid-correlated ADRs. The three main ADRs are hematologic toxicity, peripheral neuropathy, and optic neuritis. In addition, gastrointestinal disorder and hyperlactatemia are reported as ADRs too. Varied doses of linezolid were used in the seven articles; they range from 300 mg to 1200 mg, with 600 mg\/twice daily and 1200 mg\/day being dominant. Conclusions: Linezolid-associated ADRs are dose- and duration-dependent. Hematological toxicity most commonly occurs at the beginning of treatment, while peripheral neuropathy and optic neuritis appear after long-term use. Therefore, intensive monitoring and therapeutic drug monitoring are essential to ensure the safety of linezolid therapy.<\/jats:p>","DOI":"10.3390\/medsci14010003","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T11:43:31Z","timestamp":1766403811000},"page":"3","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adverse Drug Reaction to Linezolid in Drug-Resistant Tuberculosis: A Systematic Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9213-7888","authenticated-orcid":false,"given":"Emy","family":"Oktaviani","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Bandung Institute of Technology, Bandung 40132, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9879-6112","authenticated-orcid":false,"given":"Kusnandar","family":"Anggadiredja","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Bandung Institute of Technology, Bandung 40132, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0011-1558","authenticated-orcid":false,"given":"Lia","family":"Amalia","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Bandung Institute of Technology, Bandung 40132, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2025). Global Tuberculosis Report, WHO."},{"key":"ref_2","unstructured":"Ministry of Health, Indonesia (2025, November 30). Dashboard of Tuberculosis in Indonesia; Jakarta, Indonesia. Available online: https:\/\/www.tbindonesia.or.id\/pustaka-tbc\/data-kondisi-tbc\/."},{"key":"ref_3","unstructured":"World Health Organization (2025). WHO Operational Handbook on Tuberculosis: Module 4: Treatment and Care, WHO."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/ijmy.ijmy_57_21","article-title":"Early safety and efficacy of linezolid-based combination therapy among patients with drug-resistant tuberculosis in North-western Nigeria","volume":"10","author":"Dayyab","year":"2021","journal-title":"Int. J. Mycobacteriology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1183\/09031936.00035114","article-title":"Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: A study in China","volume":"45","author":"Tang","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e02012-19","DOI":"10.1128\/AAC.02012-19","article-title":"Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis","volume":"64","author":"Diacon","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12941-023-00655-2","article-title":"Effectiveness and safety of regimens containing linezolid for treatment of Mycobacterium abscessus pulmonary Disease","volume":"22","author":"Cheng","year":"2023","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Khan, F.U., Khan, A., Khan, F.U., Hayat, K., Rehman, A.u., Chang, J., Khalid, W., Noor, S., Khan, A., and Fang, Y. (2022). Assessment of Adverse Drug Events, Their Risk Factors, and Management Among Patients Treated for Multidrug-Resistant TB: A Prospective Cohort Study From Pakistan. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.876955"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jointm.2022.12.003","article-title":"Nomogram prediction model called \u201cADPLCP\u201d for predicting linezolid-associated thrombocytopenia in elderly individuals","volume":"3","author":"Liu","year":"2023","journal-title":"J. Intensive Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jointm.2022.05.006","article-title":"Clinical efficacy and safety of linezolid in intensive care unit patients","volume":"3","author":"Ma","year":"2023","journal-title":"J. Intensive Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e01591","DOI":"10.1016\/j.idcr.2022.e01591","article-title":"Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients","volume":"29","author":"Oehadian","year":"2022","journal-title":"IDCases"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/jac\/dkac019","article-title":"Linezolid toxicity in patients with drug-resistant tuberculosis: A prospective cohort study","volume":"77","author":"Wasserman","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3201\/eid2608.191499","article-title":"Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France","volume":"26","author":"Jaspard","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/ijpp.12543","article-title":"Haematological adverse effects associated with linezolid in patients with drug-resistant tuberculosis: An exploratory study","volume":"27","author":"Letswee","year":"2019","journal-title":"Int. J. Pharm. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yuan, Y., Li, J., Chen, Y., Cai, Q., Xu, Y., Lin, L., Lang, Y., Guo, S., Zhang, R., and Cai, X. (2022). Mechanism underlying linezolid-induced peripheral neuropathy in multidrug-resistant tuberculosis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.946058"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Bano, S., Nawaz, A., Numan, A., Hassan, M.A., and Shafique, M.B.A. (2022). A Case Report and Literature Review of the Outcome of Linezolid-Induced Optic and Peripheral Neuropathy in Patients with Multidrug-Resistant Pulmonary TB. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.908584"},{"key":"ref_17","first-page":"127","article-title":"Ocular side effects in tuberculosis patients receiving direct observed therapy containing ethambutol","volume":"12","author":"Dave","year":"2021","journal-title":"Natl. J. Physiol. Pharm. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Padmapriyadarsini, C., Solanki, R., Jeyakumar, S.M., Bhatnagar, A., Muthuvijaylaksmi, M., Jeyadeepa, B., Reddy, D., Shah, P., Sridhar, R., and Vohra, V. (2023). Linezolid Pharmacokinetics and Its Association with Adverse Drug Reactions in Patients with Drug-Resistant Pulmonary Tuberculosis. Antibiotics, 12.","DOI":"10.3390\/antibiotics12040714"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5588\/ijtld.11.0493","article-title":"Linezolid in the treatment of MDR-TB: A retrospective clinical study","volume":"16","author":"Xu","year":"2012","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/cid\/ciac528","article-title":"Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis","volume":"76","author":"Padmapriyadarsini","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jac\/dkl298","article-title":"Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis","volume":"58","author":"Park","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1183\/09031936.00009509","article-title":"A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis","volume":"34","author":"Migliori","year":"2009","journal-title":"Eur. Respir. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/jac\/dkp171","article-title":"Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis","volume":"64","author":"Koh","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/cid\/ciab699","article-title":"Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis","volume":"74","author":"Imperial","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijantimicag.2006.04.017","article-title":"High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency","volume":"28","author":"Lin","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijantimicag.2010.02.019","article-title":"Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction","volume":"36","author":"Matsumoto","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/jac\/dky096","article-title":"Linezolid pharmacokinetics in MDR-TB: A systematic review, meta-analysis and Monte Carlo simulation","volume":"73","author":"Millard","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jfma.2020.06.011","article-title":"Impact of high plasma concentrations of linezolid in Taiwanese adult patients\u2014Therapeutic drug monitoring in improving adverse drug reactions","volume":"120","author":"Cheng","year":"2021","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1086\/338403","article-title":"Thrombocytopenia Associated with Linezolid Therapy","volume":"34","author":"Attassi","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12941-016-0156-y","article-title":"Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: A systematic review and meta-analysis","volume":"15","author":"Agyeman","year":"2016","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/jcpt.13359","article-title":"Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients","volume":"46","author":"Dai","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1128\/AAC.46.8.2723-2726.2002","article-title":"Hematologic Effects of Linezolid: Summary of Clinical Experience","volume":"46","author":"Gerson","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/jcpt.12762","article-title":"Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study","volume":"44","author":"Kim","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","article-title":"Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections","volume":"41","author":"Cattaneo","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/jpp.JPP_167_16","article-title":"Mechanism Underlying Linezolid-induced Thrombocytopenia in a Chronic Kidney Failure Mouse Model","volume":"8","author":"Nishijo","year":"2017","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1177\/0300060518800126","article-title":"Linezolid-induced pure red cell aplasia: A case report and literature review","volume":"46","author":"Luo","year":"2018","journal-title":"J. Int. Med. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/cid\/ciu786","article-title":"MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort. Compassionate Use of Bedaquiline for the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Interim Analysis of a French Cohort","volume":"60","author":"Guglielmetti","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1248\/bpb.b16-00427","article-title":"Linezolid-Induced Thrombocytopenia Is Caused by Suppression of Platelet Production via Phosphorylation of Myosin Light Chain 2","volume":"39","author":"Tajima","year":"2016","journal-title":"Biol. Pharm. Bull."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1345\/aph.1C361","article-title":"Mechanisms for Linezolid-Induced Anemia and Thrombocytopenia","volume":"37","author":"Bernstein","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5588\/ijtld.22.0423","article-title":"Risk factors for peripheral neuropathy in patients on linezolid-containing regimens for drug-resistant TB","volume":"27","author":"Kwon","year":"2023","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1080\/1120009X.2022.2136447","article-title":"Linezolid-related adverse effects in the treatment of rifampicin resistant tuberculosis: A retrospective study","volume":"35","author":"Cui","year":"2023","journal-title":"J. Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1473-3099(04)01109-0","article-title":"Peripheral neuropathy associated with prolonged use of linezolid","volume":"4","author":"Bressler","year":"2004","journal-title":"Lancet Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1097\/MJT.0000000000000359","article-title":"Linezolid Induced Reversible Peripheral Neuropathy","volume":"23","author":"Vishnu","year":"2016","journal-title":"Am. J. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.2147\/IDR.S365371","article-title":"Linezolid-Associated Neuropathy in Patients with MDR\/XDR Tuberculosis in Shenzhen, China","volume":"15","author":"Zhang","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1473-3099(24)00228-7","article-title":"Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: A prospective cohort study-PubMed","volume":"24","author":"Korotkyi","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.2169\/internalmedicine.1344-18","article-title":"Is Severe and Long-lasting Linezolid-induced Optic Neuropathy Reversible?","volume":"57","author":"Lee","year":"2018","journal-title":"Intern Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.sjopt.2018.10.010","article-title":"Linezolid induced optic neuropathy in a child treated for extensively drug resistant tuberculosis: A case report and review of literature","volume":"33","author":"Agashe","year":"2019","journal-title":"Saudi J. Ophthalmol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Mehta, S., Das, M., Laxmeshwar, C., Jonckheere, S., Thi, S.S., and Isaakidis, P. (2016). Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162138"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3341\/jkos.2019.60.12.1363","article-title":"Optic Neuropathy after Taking Linezolid","volume":"60","author":"Yoon","year":"2019","journal-title":"J. Korean Ophthalmol. Soc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijtb.2023.06.016","article-title":"Linezolid induced toxic optic neuropathy in drug resistant tuberculosis-A case series","volume":"71","author":"Vallabhaneni","year":"2024","journal-title":"Indian J. Tuberc."},{"key":"ref_53","first-page":"61","article-title":"Optic neuropathy associated with linezolid: Systematic review of cases","volume":"43","year":"2019","journal-title":"Farm. Hosp."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jsps.2021.12.021","article-title":"Successful treatment of linezolid-induced severe lactic acidosis with continuous venovenous hemodiafiltration: A case report","volume":"30","author":"Zhang","year":"2022","journal-title":"Saudi Pharm. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4046\/trd.2021.0122","article-title":"Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Role of Mitochondria","volume":"85","author":"Oehadian","year":"2022","journal-title":"Tuberc. Respir. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1128\/AAC.01185-10","article-title":"Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients","volume":"55","author":"Sasaki","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1128\/AAC.01378-08","article-title":"Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis","volume":"53","author":"McGee","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Lin, B., Hu, Y., Xu, P., Xu, T., Chen, C., He, L., Zhou, M., Chen, Z., Zhang, C., and Yu, X. (2022). Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.967311"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/jcpt.13747","article-title":"Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid-associated thrombocytopenia","volume":"47","author":"Onita","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e00687-17","DOI":"10.1128\/AAC.00687-17","article-title":"Systematic therapeutic drug monitoring for linezolid: Variability and clinical impact","volume":"61","author":"Galar","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17512433.2023.2181160","article-title":"Hematological toxicities associated with linezolid therapy in adults: Key findings and clinical considerations","volume":"16","author":"Cattaneo","year":"2023","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1901903","DOI":"10.1183\/13993003.01903-2019","article-title":"Therapeutic drug monitoring using saliva as matrix: An opportunity for linezolid, but challenge for moxifloxacin","volume":"55","author":"Akkerman","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/FTD.0b013e3181cc6d6f","article-title":"Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis","volume":"32","author":"Alffenaar","year":"2010","journal-title":"Ther. Drug Monit."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"102367","DOI":"10.1016\/j.tube.2023.102367","article-title":"Limited sampling strategies for therapeutic drug monitoring of anti-tuberculosis medications: A systematic review of their feasibility and clinical utility","volume":"141","author":"Xavier","year":"2023","journal-title":"Tuberculosis"}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/1\/3\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:05:27Z","timestamp":1766405127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/1\/3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["medsci14010003"],"URL":"https:\/\/doi.org\/10.3390\/medsci14010003","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}